Shareholders Equity: The sum of preferred and common equity items.
Takeda Pharmaceutical Co. (TAK) had Shareholders Equity of $49.69B for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$20.26B |
|
$13.55B |
|
$79.90B |
|
$100.16B |
|
$16.97B |
|
$27.76B |
|
$33.50B |
|
$50.47B |
|
$49.69B |
|
$-10.56B |
|
|
Shareholders Equity |
$49.69B |
3.16B |
|
| Cash Flow Statement Financials | |
$6.28B |
|
$-2.02B |
|
$-2.73B |
|
$2.50B |
|
$4.26B |
|
$1.75B |
|
$344.92M |
|
$-1.97B |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|